Consistent with the CRISPR screen result that DOT1L HMTase is a codependency with INCB treatment, co-treatment with INCB and the DOT1L inhibitor EPZ5676 synergistically induced lethality in AML and sAML cells (Fig. S15A)46. This evidence concerns the gene DOT1L and acute myeloid leukemia.